This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Effectiveness results
During the two seasons, 16 of the 42 patients were hospitalised. Ten had RSV infection, 2 had adenovirus, 1 had measles pneumonia and 3 had negative virologic diagnosis tests. Therefore, the average hospitalisation rate due to RSV infection was 23.8% (95% confidence interval: 12 -39). The hospitalisation rate was 33% in 1998 and 16% in 1999.
Clinical conclusions
The effectiveness study showed that a very high hospitalisation rate was associated with RSV infection in high-risk patients.
Outcomes assessed in the review
The outcome assessed was the reduction in the hospitalisation rate due to palivizumab. This was estimated from the literature.
Study designs and other criteria for inclusion in the review
Not stated.
Sources searched to identify primary studies
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Only one study was used.
Methods of combining primary studies
Not relevant (single study used).
Results of the review
The reduction in the hospitalisation rate due to palivizumab was 55%.
Measure of benefits used in the economic analysis
The summary benefit measure used was the reduction in the hospitalisation rate. This was derived from the published study.
Direct costs
Discounting was not applied since the costs were incurred during less than two years. The unit costs were reported but the quantities of resources used were not. The health services included in the economic evaluation were palivizumab and administration costs, and hospitalisation in a paediatric room or neonatal intensive care unit. It was assumed that there would be no drug wastage. The cost/resource boundary of the study was unclear. Resource use was estimated using data retrospectively gathered in 1998 and 1999 from the sample of patients who were involved in the effectiveness study. The costs were estimated from manufacturers' prices and from the Department of Costs at the study hospital. The price year was 2000.
Statistical analysis of costs
No statistical tests of the costs were performed.
Indirect Costs
The indirect costs were not considered in the economic evaluation.
Currency

US dollars ($).
Sensitivity analysis
One-way sensitivity analyses were carried out to address the issue of uncertainty in the hospitalisation rate. The ranges of variations explored were the confidence interval and the 1998 and 1999 rates observed in the single study.
Estimated benefits used in the economic analysis
The hospitalisation rate was 23.8% without palivizumab, as observed in the single study. This was reduced by 55%, as reported in the published study. The actual figure for the hospitalisation rate with palivizumab was not reported.
Cost results
In the whole group, the cost of hospitalisation was $184,777. The cost of hypothetical palivizumab use would be $185,064.
Synthesis of costs and benefits
The authors stated that, applying the 55% reduction in hospitalisation, the cost per avoided hospitalisation was $15,358 and the number-needed-to-treat was 7.9. The process used to calculate these figures was unclear. The sensitivity analysis showed that the cost to avoid one hospitalisation decreased when the rate of hospitalisation increased. present cost-effectiveness study represented an important instrument to assist decision-making in developing countries.
CRD COMMENTARY -Selection of comparators
The choice of the comparator (no intervention) appears to have been appropriate because it permitted the additional value of palivizumab to be assessed. You should decide whether no intervention represents a valid comparator in your own setting.
Validity of estimate of measure of effectiveness
The analysis of effectiveness was based on a historical case series for patients in the no intervention group, and on data from a published study for the outcome associated with the study intervention. With the use of a historical case series, the design of the study was weak since a single group of patients was considered and a retrospective analysis was carried out. A prospective trial would have provided more reliable results. The data that were derived from the literature came from a study whose details were not provided. Only the reduction in the hospitalisation rate was reported. Thus, it was difficult to estimate the validity of the source used and it was unclear whether the two populations were comparable. Sensitivity analyses were carried out on one estimate only and uncertainty around the remaining values was not investigated.
Validity of estimate of measure of benefit
The summary benefit measure was derived from the effectiveness study and was specific to the disease under evaluation. Therefore, comparisons with the benefits of other health care interventions are likely to be difficult. Further, the use of reduction in hospitalisation rate was inappropriate for assessing the impact of the intervention on the patients' health, as this represented an intermediate rather than a final measure.
Validity of estimate of costs
The true perspective adopted in the study was unclear. It appears that only the direct costs relevant to the service provided have been included, despite the fact that the authors stated that a societal perspective was adopted. The indirect costs and non-medical costs were not considered, although the authors provided a justification for such exclusions. The source of the cost data, price year and unit costs were reported, which means that replication of the study in other settings should be possible. The details of resource use were less clear. Discounting was irrelevant and was not carried out.
